Elucida Oncology Inc., a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman.
Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by Pfizer in 2009. In his 32 years in the pharmaceutical industry Mr. Essner has held numerous high-level leadership roles that included Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). He is Chairman of the not-for-profit Children’s Health Fund, and a Trustee of Mote Marine Laboratory, as well as Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in Healthcare Management.
Mr. Essner is also an Operating Executive for The Carlyle Group, and a member of the Board of Directors for Amicus Therapeutics and has just completed a 16-year term on the Board of Directors for MassMutual.
Isaac Blech, Vice Chairman of the Board of Directors of Elucida Oncology, commented, “All of us at Elucida are extremely pleased to bring an executive of Bob Essner’s stature into the company to help Elucida achieve its goal of becoming a leading precision medicine oncology company.”
“I welcome Bob to Elucida and look forward to his considerable experience being applied to the Elucida C-Dot platform as we bring to market first-in-class diagnostic and therapeutic products to positively impact the lives of cancer patients,” said Edward Rosen, Elucida’s President and Chief Executive Officer. “Bob Essner is a pivotal leader in the pharmaceutical industry. We are delighted to have Bob join us as Executive Chairman.”
“I am very excited to be part of what is being built at Elucida Oncology,” stated Mr. Essner. “Advancing innovation to change and save lives has been the core of my career for over 30 years. At Elucida, we have a remarkable first-in-class particle platform. This is a rare opportunity to make a compelling improvement to the world of precision oncology, in diagnostic and therapeutic applications. I am proud to be part of this effort and this team.”
Source: Elucida Oncology
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.